Leef Brands (LEEEF) Net Cash Flow (2025 - 2026)
Leef Brands (LEEEF) posted Net Cash Flow of $3.6 million for Q1 2026, up 296.28% sequentially from -$1.8 million in Q1 2025, and up 296.28% YoY from $899673.1 in Q1 2025.
Leef Brands (LEEEF) Net Cash Flow (2025 - 2026) Analysis & Trends
Leef Brands has reported Net Cash Flow for 2 years, with the latest figure at $3.6 million in Q1 2026.
- Quarterly Net Cash Flow rose 296.28% year-over-year to $3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (changed N/A YoY) and the FY2025 annual result came in at -$540914.0, up 85.34% from the prior year.
- Net Cash Flow grew to $3.6 million in Q1 2026 per LEEEF's latest filing, from -$1.8 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $3.6 million in Q1 2026 and troughed at -$1.8 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.36 Bn | 43.40 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.76 Bn | 40.11 Bn | 2.15 Bn | -81.00 Mn |
| 3 | Zoetis | 32.39 Bn | 30.71 Bn | 1.05 Bn | -458.00 Mn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | -881.03 Mn |
| 5 | United Therapeutics | 22.12 Bn | 19.45 Bn | 683.80 Mn | 523.50 Mn |
| 6 | Viatris | 18.87 Bn | 17.99 Bn | 1.46 Bn | -912.40 Mn |
| 7 | Neurocrine Biosciences | 15.64 Bn | 15.25 Bn | 935.80 Mn | 64.40 Mn |
| 8 | Elanco Animal Health | 11.99 Bn | 11.46 Bn | 798.00 Mn | 93.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - | - |
| 10 | Leef Brands | 59.16 Mn | 54.21 Mn | 2.41 Mn | -805,010.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -805,010.00 |
| Jun 30, 2026 | -805,010.00 |
| Mar 31, 2026 | 3.57 Mn |
| Mar 31, 2026 | 3.57 Mn |
| Mar 31, 2025 | -1.82 Mn |
| Mar 31, 2025 | -1.82 Mn |